RLYB115

Stage:Preclinical
Indication:Immuno-inflammation
Therapeutic Modality:Protein
Mechanism of Action:Undisclosed

RLYB115 is an undisclosed product candidate in development for the treatment of patients with severe, rare immuno-inflammatory diseases.